NICTA startup, Saluda Medical, receives $10 million in Series B financing

Published on February 23, 2015

“Saluda Medical has today announced that it has received $10 million in Series B financing bringing a breakthrough treatment for chronic pain one step closer to reality.

The company, a successful spin-out from NICTA, Australia’s Information Communications and Technology (ICT) Research Centre of Excellence, is developing world-first neuromodulation technologies that will improve the treatment of chronic pain, Parkinson’s disease, epilepsy and other debilitating disorders.”

Read the full article at News Medical.